Akaal Pharma is interested in exploring partnering opportunities with pharmaceuticals and biotech corporations for late-stage clinical development (Phase 2 and 3), regulatory approval and commercial launch of its internally designed, discovered and developed small molecule drug candidates for the treatment of various inflammatory, autoimmune and pain diseases.
Please contact us for partnering opportunities at email@example.com or Cell +1 (858) 925 4555 (San Diego, CA, USA) or Tel. +61 3 9479 2584 (Melbourne, Australia)
Akaal Pharma has internally discovered novel compounds (small molecule drug candidates) as highly potent and selective modulators of Sphingosine 1-Phosphate receptors -1 (S1P1) useful in the treatment of autoimmune and inflammatory diseases. The proprietary compounds have displayed multimodal action and have proven human proof of concept in inflammatory, autoimmune and pain indications. Akaal Pharma owns all commercialization and intellectual property (IP) rights to its internally produced IP.
Our Phase-2 clinical candidate AKP-11 (various topical formulations) is a First-in-class topical treatment for the atopic dermatitis, psoriasis and arthritis. In the Phase-1 clinical trials, our lead product has demonstrated both safety and efficacy.
Our oral drug candidate is ready for commencing Phase-1 clinical trial is a potential Best-in-class S1P1 modulators. The oral drug candidates are directed at the treatment of autoimmune and inflammatory disease such as multiple sclerosis and ulcerative colitis, Crohn’s disease and rheumatoid arthritis. The major advantages of our oral drug candidate isselectivity, receptor safety, reversible lymphopenia, broad therapeutic window and pharmacokineticsprofileas multiple differentiation points and has a superior profile.